Rutgers Cancer Institute

Articles

Expert Commentary: Insights into Cancer Mutation Patterns

April 4th 2024

Researchers at Rutgers Cancer Institute of New Jersey provided commentary on how changes in the structure of DNA influence the mutation patterns in cancer.

Exploring Disparities in Colorectal Cancer

March 30th 2024

Health systems have put a stronger emphasis on making preventive care accessible, contributing to a reduction in colorectal cancer incidence and mortality.

RWJBarnabas Health and Rutgers Cancer Institute of New Jersey First in State Offering Novel Form of Liver Cancer Treatment

February 16th 2024

Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health will offer hepatic artery infusion therapy for patients with liver tumors.

Rutgers Cancer Institute of New Jersey Unveils Leadership Enhancements for Next Era of Excellence

February 13th 2024

Rutgers Cancer Institute of New Jersey has elevated 2 associate director functions to deputy director positions.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Expansive Portfolio of Hematology/Oncology Data at the 65th American Society of Hematology Annual Meeting and Exposition

December 14th 2023

Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present an extensive array of hematology/oncology data from their clinical research program at the 65th American Society of Hematology Annual Meeting and Exposition, being held in San Diego, California from December 9-12, 2023.

New Chief of Cancer Survivorship Named to New Jersey’s Only NCI-Designated Comprehensive Cancer Center

December 11th 2023

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health has appointed Louise Ligresti, MD, as chief of Cancer Survivorship at New Jersey’s leading cancer center and the only one in the state designated as a Comprehensive Cancer Center by the National Cancer Institute.

RWJBarnabas Health Recognized Among 2023’s “100 Hospitals and Health Systems with Great Oncology Programs" by Becker’s Hospital Review

October 13th 2023

RWJBarnabas Health, together with Rutgers Cancer Institute of New Jersey, has been named among Becker’s Hospital Review’s 100 Hospitals and Health Systems with Great Oncology Programs for 2023.

Multiple Myeloma: The Black Community, Disparities & Clinical Trials

September 21st 2023

The incidence of multiple myeloma, a rare and incurable cancer of a person’s plasma cells that fight infection and disease, is more than two times higher in Black people compared to white people according to the American Cancer Society’s 2022-2024 Cancer Facts & Figures for African American/Black People.

Addressing the Challenge: Connecting Black Women with Clinical Trials

April 26th 2023

Clinical trials have strikingly low rates of Black participants, even those centered on diseases that disproportionately affect Black women in particular, such as breast cancer, the most commonly diagnosed cancer and the leading cause of cancer death for this population.

Chief of Urologic Oncology Addresses Young Men’s Common Concerns about Testicular Cancer

April 14th 2023

Though testicular cancer can impact males of any age, it generally affects men in their 20s and 30s. The average age at the time of diagnosis of testicular cancer is about 33, according to the American Cancer Society.

$3.2 Million Grant Supports Study of New Genetic Testing Approach to Reduce Racial Health Disparities

April 3rd 2023

With a National Cancer Institute grant, investigators from Rutgers Cancer Institute of New Jersey and Georgetown University’s Lombardi Comprehensive Cancer Center will work to close racial disparity gaps in cancer care delivery by examining a novel approach to genetic testing and care based on community identified needs.

Neil Palmisiano, MD, Appointed as Deputy Director of Phase 1 Therapeutics for Hematologic Malignancies at Rutgers Cancer Institute of New Jersey

October 10th 2022

Further enhancing its focus on providing outstanding, innovative and compassionate care for cancer patients, Rutgers Cancer Institute of New Jersey, the state’s leading cancer center and only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, are welcoming a new leader to its team of internationally recognized physicians and researchers.

Exploring Cancer and Health Data on Asian American and Pacific Islanders

August 30th 2022

Antoinette Stroup, PhD, shares personal and professional insight on the disaggregation of cancer health statistics regarding the Asian American and Pacific Islander community.

Rutgers Cancer Institute Research Leader Eileen White Named Rutgers Board of Governors Professor of Molecular Biology and Biochemistry

July 8th 2022

The Rutgers Board of Governors has named Rutgers Cancer Institute of New Jersey Deputy Director Eileen White, PhD, the Board of Governors Professor of Molecular Biology and Biochemistry at the Rutgers School of Arts and Sciences for her contributions to science and leadership in the fields of apoptosis, autophagy and cancer metabolism.

ANCHOR Study Shows Treatment of Precancerous Lesions in Individuals Living With HIV Reduces Anal Cancer Risk by Half

July 5th 2022

Results from a study of individuals living with HIV show treatment of a precancerous condition known high-grade squamous intraepithelial lesions of the anus cuts the risk of developing anal cancer in this population by more than half.

Radiation Therapy as Effective as Surgery for Prostate Cancer

June 30th 2022

Ronald D. Ennis, MD, shares how radiotherapy is an excellent treatment for many men with prostate cancer, providing a minimally-invasive treatment with low adverse effect risks.

New Jersey’s Only NCI-designated Comprehensive Cancer Center Names Director for Phase I Clinical Trials and Investigational Therapeutics

February 16th 2022

Rutgers Cancer Institute of New Jersey has named Sanjay Goel, MD, MS as director of its Phase I/Investigational Therapeutics Program.